Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15491MR)

This product GTTS-WQ15491MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15491MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13022MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ12508MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ2406MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ12893MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ3485MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ12353MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ4624MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ7234MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.